Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.3K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.3K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improving physiological fidelity of in vitro knee simulators through bidirectional optimized muscle control.

Journal of biomechanics·2026
Same author

Critical regions in the human mandible during mastication and trauma: a finite element study.

Journal of medical engineering & technology·2026
Same author

Comparing the importance of implant customization vs. usage of a fibular graft using a novel mandibular implant for improved reconstruction: a finite element study.

Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery·2025
Same author

Pharmacogenetic exploration of buprenorphine and related metabolites in umbilical cord blood.

Toxicology reports·2025
Same author

Radiographic Assessment of Total Knee Arthroplasty Alignment With and Without Accelerometer-Based Navigation at a Resident Training Institution.

The journal of knee surgery·2024
Same author

A scoping review of applications of artificial intelligence in kinematics and kinetics of ankle sprains - current state-of-the-art and future prospects.

Clinical biomechanics (Bristol, Avon)·2024

Related Experiment Video

Updated: May 3, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

8.6K

Steroid resistance in leukemia.

Darshan S Shah1, Raj Kumar1

  • 1Darshan S Shah, Raj Kumar, Department of Basic Sciences, The Commonwealth Medical College, Scranton, PA 18509, United States.

World Journal of Experimental Medicine
|February 13, 2014
PubMed
Summary
This summary is machine-generated.

Glucocorticoids (GCs) treat leukemia but prolonged use can cause steroid-resistance. Understanding GC resistance mechanisms is key to developing better leukemia treatments.

Keywords:
GenesGlucocorticoidLeukemiaMutationsSteroid resistant

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.4K

Related Experiment Videos

Last Updated: May 3, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

8.6K
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

2.7K
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Cell Biology

Background:

  • Leukemia involves abnormal myeloid or lymphoid cell growth.
  • Glucocorticoids (GCs) are used to treat various leukemias due to their lympholytic effects.
  • Initial response to GCs in acute lymphoblastic leukemia can be followed by steroid-resistance.

Purpose of the Study:

  • To explore the mechanisms of glucocorticoid resistance in leukemia.
  • To identify factors contributing to therapeutic resistance in leukemia patients.
  • To inform the development of novel therapeutic strategies for leukemia.

Main Methods:

  • Review of existing literature on glucocorticoid action and resistance in leukemia.
  • Analysis of correlations between glucocorticoid receptor expression and treatment outcomes.
  • Investigation of emerging mechanisms of drug resistance in leukemic cells.

Main Results:

  • A correlation exists between functional glucocorticoid receptor levels and steroid-resistance.
  • Several other mechanisms contribute to drug resistance in leukemia.
  • The precise mechanisms of steroid-resistance are not fully understood.

Conclusions:

  • Understanding glucocorticoid resistance is crucial for improving leukemia treatment.
  • Further research into resistance mechanisms can guide the design of more effective drugs.
  • Targeting resistance pathways may enhance therapeutic outcomes for leukemia patients.